Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats

Toxicol Appl Pharmacol. 2015 Nov 15;289(1):1-11. doi: 10.1016/j.taap.2015.08.017. Epub 2015 Sep 1.

Abstract

The clinical efficacy of anthracycline anti-neoplastic agents is limited by cardiac and hepatic toxicities. The aim of this study was to assess the hepatoprotective and cardioprotective effects of taurine zinc solid dispersions, which is a newly-synthesized taurine zinc compound, against doxorubicin-induced toxicity in Sprague-Dawley rats intraperitoneally injected with doxorubicin hydrochloride (3mg/kg) three times a week (seven injections) over 28 days. Hemodynamic parameters, levels of liver toxicity markers and oxidative stress were assessed. Taurine zinc significantly attenuated the reductions in blood pressure, left ventricular pressure and ± dp/dtmax, increases in serum alanine aminotransferase and aspartate aminotransferase activities, and reductions in serum Zn(2+) and albumin levels (P<0.05 or 0.01) induced by doxorubicin. In rats treated with doxorubicin, taurine zinc dose-dependently increased liver superoxide dismutase activity and glutathione concentration, and decreased malondialdehyde level (P<0.01). qBase(+) was used to evaluate the stability of eight candidate reference genes for real-time quantitative reverse-transcription PCR. Taurine zinc dose-dependently increased liver heme oxygenase-1 and UDP-glucuronyl transferase mRNA and protein expression (P<0.01). Western blotting demonstrated that taurine zinc inhibited c-Jun N-terminal kinase phosphorylation by upregulating dual-specificity phosphoprotein phosphatase-1. Additionally, taurine zinc inhibited cardiomyocyte apoptosis as there was decreased TUNEL/DAPI positivity and protein expression of caspase-3. These results indicate that taurine zinc solid dispersions prevent the side-effects of anthracycline-based anticancer therapy. The mechanisms might be associated with the enhancement of antioxidant defense system partly through activating transcription to synthesize endogenous phase II medicine enzymes and anti-apoptosis through inhibiting JNK phosphorylation.

Keywords: Apoptosis; Doxorubicin; Heme oxygenase-1; Taurine zinc solid dispersions; UDP-glucuronosyl transferase; c-Jun N-terminal kinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Alanine Transaminase / blood
  • Animals
  • Anthracyclines / adverse effects
  • Antibiotics, Antineoplastic / pharmacology
  • Antioxidants / pharmacology
  • Apoptosis / drug effects
  • Aspartate Aminotransferases / blood
  • Cardiotoxicity / drug therapy*
  • Chemical and Drug Induced Liver Injury / drug therapy*
  • Dose-Response Relationship, Drug
  • Doxorubicin / adverse effects*
  • Glucuronosyltransferase / genetics
  • Glucuronosyltransferase / metabolism
  • Glutathione / metabolism
  • Heart / drug effects
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Liver / drug effects
  • Male
  • Malondialdehyde / blood
  • Minor Histocompatibility Antigens
  • Mitogen-Activated Protein Kinase 8 / genetics
  • Mitogen-Activated Protein Kinase 8 / metabolism
  • Oxidative Stress / drug effects
  • Phosphorylation
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Taurine / pharmacology*
  • Up-Regulation
  • Zinc / pharmacology*

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • Antioxidants
  • Minor Histocompatibility Antigens
  • RNA, Messenger
  • Ugt1a1 protein, rat
  • Taurine
  • Malondialdehyde
  • Doxorubicin
  • Heme Oxygenase-1
  • Glucuronosyltransferase
  • glucuronosyltransferase 2B, rat
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Mitogen-Activated Protein Kinase 8
  • Glutathione
  • Zinc